Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

392
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
392
Tissue Transplantation01:24

Tissue Transplantation

883
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
883
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

846
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
846

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current landscape of academic and point of care CAR-T cell therapy in low-middle income countries.

Clinical hematology international·2026
Same author

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026
Same author

Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.

Bone marrow transplantation·2026
Same author

Real-World Practice Patterns in Diagnosis and First-Line Treatment in Metastatic Breast Cancer.

The breast journal·2026
Same author

Incidence and Risk Factors for CNS Relapse in Adult ALL after Allogeneic Hematopoietic Cell Transplantation.

Blood advances·2026
Same author

Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma.

Blood neoplasia·2026
Same journal

Comment on "Poor graft function (PGF) following in vivo T cell-depleted allogeneic stem cell transplantation: the role of delayed immune reconstitution".

Transplantation and cellular therapy·2026
Same journal

A Simplified Frailty Score Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.

Transplantation and cellular therapy·2026
Same journal

Facilitation Of Related Donor Haematopoietic Stem Cell Donation By Unrelated Donor Registries: Recommendations From The World Marrow Donor Association.

Transplantation and cellular therapy·2026
Same journal

System-Level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated with High 1-Year Survival and Reduced Cost.

Transplantation and cellular therapy·2026
Same journal

Peritransplant KMT2A-r Molecular MRD Dynamics and Relapse Timing Stratify Outcomes After Allo-HSCT in CR1 Acute Leukemia.

Transplantation and cellular therapy·2026
Same journal

Harnessing the Power of Two: High-Dose Stem Cell Haploidentical Transplant in Hematologic Malignancies - A Prospective Trial.

Transplantation and cellular therapy·2026
See all related articles

Related Experiment Video

Updated: Jan 11, 2026

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.8K

A Practical Guide to Competing Risk Analysis for Transplant and Cell Therapy Research.

Héctor A Vaquera-Alfaro1, Yein Jeon2, Qian Vicky Wu3

  • 1Servicio de Hematología, Hospital Universitario "Dr. José Eleuterio González," Universidad Autónoma de Nuevo León, Monterrey, México.

Transplantation and Cellular Therapy
|November 8, 2025
PubMed
Summary
This summary is machine-generated.

Hematopoietic cell transplantation (HCT) and immune effector cell (IEC) therapies face challenges with competing risks like treatment-related mortality. This guide provides clinicians with practical steps for analyzing time-to-event data with competing risks using R.

Keywords:
Competing risks analysisCumulative incidenceHematopoietic cell transplantImmune-effector cell therapyRStudio

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K
Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model
10:11

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model

Published on: March 7, 2013

15.8K

Related Experiment Videos

Last Updated: Jan 11, 2026

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.8K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K
Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model
10:11

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model

Published on: March 7, 2013

15.8K

Area of Science:

  • Biostatistics
  • Clinical Research
  • Hematology

Background:

  • Competing risks are prevalent in hematopoietic cell transplantation (HCT) and immune effector cell (IEC) therapy research.
  • These risks, such as treatment-related mortality competing with disease relapse, complicate standard time-to-event analyses.
  • Robust statistical methods are crucial for accurate interpretation of outcomes in these fields.

Purpose of the Study:

  • To introduce the fundamental concepts of statistical modeling for competing risks in a clinician-friendly manner.
  • To provide a practical, step-by-step guide for analyzing time-to-event outcomes with competing risks.
  • To facilitate the use of the open-access R environment for such analyses.

Main Methods:

  • Explanation of core statistical concepts for competing risk modeling.
  • A practical guide to analyzing time-to-event data using the R statistical environment.
  • Introduction to relevant R packages for generating publication-ready tables and figures.

Main Results:

  • The manuscript outlines a clear methodology for addressing competing risks in HCT and IEC research.
  • It demonstrates the application of specific R packages for data analysis.
  • The proposed methods allow for the creation of interpretable results, including tables and figures.

Conclusions:

  • This primer equips clinicians with the knowledge and tools to perform robust competing risk analyses.
  • Encourages the adoption of advanced statistical methods in HCT and IEC research.
  • Aims to improve the quality and reliability of research findings in these complex therapeutic areas.